Apotex, the Canadian pharmaceutical giant, has used sensitive Teva trade secrets transferred to it by the company’s CEO, a former senior Teva executive, according to a lawsuit filed last week by the Israeli pharmaceutical giant.
According to the report, in a lawsuit filed in federal court in Pennsylvania, Teva claims that the secrets given by the spouse to the CEO include, among other things, sensitive information about the development of new Teva products.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
The lawsuit alleges that Brender Sandhu, formerly Teva’s director of regulatory relationships in the US, provided confidential information to Apotex CEO Jeremy Desai, with whom she had a romantic relationship. Apotex used this information unfairly to promote its products and respond to Teva’s development, the lawsuit alleges.
Teva claims that Sandhu has sent confidential documents to the Desai mailbox in Apotex, as well as to his private e-mail boxes, told him oral secrets, uploaded sensitive documents to the cloud from Teva, and copied some of the screens to a disk-on-key The confidential information was conveyed to her husband, the lawsuit alleges. The documents included reference to the development of the machine in the claim – “Product X.”
“At least in one case Apotex employees spoke freely about Teva’s trade secrets in the US and discussed other confidential information related to Product X and participated in a roundtable to promote the commercial potential of Apotex and its rival generic product,” Teva said.
According to the company, according to the report, Sandhu violated its contractual obligations and its duty of trust towards the company under being a Teva employee. The company demands compensation from the employee for the malicious transfer of trade secrets and confidential information, as well as punitive damages and attorneys’ fees.
According to the lawsuit, Apotex and Desai “should be held responsible, because they encouraged Sandhu to breach the confidentiality agreement that she signed with Teva.”
The Israeli pharmaceutical giant is demanding compensation from Apotex and Desai. “Teva will seek to exercise its rights in this matter to protect its trade secrets and confidential business information,” a company spokesman said, according to Law360.
